Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06491472

Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

Efficacy and Safety of Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer：A Single-arm, Open-label, Phase II Clinical Study

Sponsor: Akesobio

Conditions Pancreatic Cancer

Interventions Gemcitabine Ivonescimab Nab paclitaxel SBRT

Updated 4 times since 2024 Last updated: Jul 8, 2024 Started: Jul 15, 2024 Primary completion: Jul 15, 2026 Completion: Jul 15, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pancreatic Cancer and is currently actively recruiting participants. Akesobio leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Aug 2025 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2

First recorded

Jul 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akesobio
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Data source: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China